CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05958121
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:58.248470+00:00
- Published At
- 2025-11-18T00:00:00+00:00
- Record Updated At
- 2025-11-18
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Refractory Cancer", "Recurrent Cancer", "Solid Tumor, Adult", "Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-18"- protocolSection.identificationModule.nctId
"NCT05958121"- protocolSection.identificationModule.officialTitle
"A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER\u00ae Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.